Skip to main content

Treatment of Acromegaly with SMS 201–995 (Sandostatin®): Clinical, Biochemical and Morphologic Study

  • Conference paper
Sandostatin® in the Treatment of Acromegaly

Abstract

Current therapy of acromegaly is unsatisfactory, and in a significant proportion of acromegalic patients the disease remains clinically active after all approved therapeutic modalities (surgery, irradiation and bromocriptine) have been exhausted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ (1988) Treatment of acromegaly with the long-acting somatostatin analogue SMS 201-995. J Clin Endocrinol Metab 66: 16

    Article  CAS  PubMed  Google Scholar 

  2. Barkan AL, Shenker Y, Grekin RJ, Vale WW (1988) Acromegaly due to ectopic GHRH secretion by malignant carcinoid tumor: successful treatment with long-acting somatostatin analogue SMS 201-995. Cancer 61: 221

    Article  CAS  PubMed  Google Scholar 

  3. Billestrup N, Swanson LW, Vale WW (1986) Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA 83: 6854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chiodini PG, Cozzi R, Dallabonzana D, Opizzi G, Verde G, Petroncini M, Liuzzi A, Del Pozo E (1987) Medical treatment of acromegaly with SMS 201-995, a somatostatin analogue: a comparison with bromocriptine. J Clin Endocrinol Metab 64: 447

    Article  CAS  PubMed  Google Scholar 

  5. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD (1985) Bombesin-line peptides can function as auto-crine growth factors in human small-cell lung cancer. Nature 316: 823

    Article  CAS  PubMed  Google Scholar 

  6. Landolt AM, Keller PJ, Froesch ER, Mueller J (1982) Bromocriptine: does it jeopardize the result of later surgery for prolactinomas? Lancet II: 657

    Article  Google Scholar 

  7. Reubi JC, Heitz PU, Landolt AM (1987) Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 65: 65

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag, Berlin Heidelberg

About this paper

Cite this paper

Barkan, A.L. et al. (1988). Treatment of Acromegaly with SMS 201–995 (Sandostatin®): Clinical, Biochemical and Morphologic Study. In: Lamberts, S.W.J. (eds) Sandostatin® in the Treatment of Acromegaly. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73694-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73694-0_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73696-4

  • Online ISBN: 978-3-642-73694-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics